Prospective Study of the Efficacy of Breast Magnetic Resonance Imaging and Mammographic Screening in Survivors of Hodgkin Lymphoma

DOI Web Site 被引用文献1件
  • Andrea K. Ng
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • Judy E. Garber
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • Lisa R. Diller
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • Robyn L. Birdwell
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • Yang Feng
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • Donna S. Neuberg
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • Barbara Silver
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • David C. Fisher
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • Karen J. Marcus
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.
  • Peter M. Mauch
    Andrea K. Ng, Robyn L. Birdwell, Barbara Silver, Karen J. Marcus, and Peter M. Mauch, Brigham and Women's Hospital; and Andrea K. Ng, Judy E. Garber, Lisa R. Diller, Yang Feng, Donna S. Neuberg, Barbara Silver, David C. Fisher, Karen J. Marcus, and Peter M. Mauch, Dana-Farber Cancer Institute, Boston, MA.

説明

<jats:sec><jats:title>Purpose</jats:title><jats:p> Current guidelines recommend breast magnetic resonance imaging (MRI) as an adjunct to mammography for breast cancer screening in female cancer survivors treated with chest irradiation at a young age, beginning 8 to 10 years after treatment. Prospective data evaluating its efficacy in female cancer survivors are lacking. This study sought to compare the sensitivity and specificity of breast MRI with those of mammography in women who received chest irradiation for Hodgkin lymphoma (HL). </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We enrolled 148 women treated with chest irradiation for HL at age ≤ 35 years who were > 8 years beyond treatment. Yearly breast MRI and mammogram were performed over a 3-year period. Sensitivity and specificity of the two screening modalities were compared. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> With the screening, 63 biopsies were performed in 45 women; 18 (29%) showed a malignancy. All but one of the screen-detected malignancies were preinvasive or subcentimeter node-negative breast cancers. After excluding first-screen MRI and mammogram, mammogram sensitivity was 68% as compared with 67% for MRI (P = 1.0). Sensitivity increased to 94% using both screening modalities. The specificities of mammogram alone, MRI alone, and both were 93%, 94%, and 90%, respectively. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> In contrast to women with genetic or familial risk, in HL survivors breast MRI was not more sensitive than mammogram for breast cancer detection. However, the two screening modalities complement each other in the detection of early cases of disease. Early diagnosis is particularly important in these patients, given the breast cancer treatment challenges in patients who have received prior cancer therapy. </jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ